Iterum Therapeutics (NASDAQ:ITRM) Stock Price Down 1.1% – Should You Sell?

Iterum Therapeutics PLC (NASDAQ:ITRM) shares dropped 1.1% on Tuesday . The company traded as low as $0.34 and last traded at $0.3502. Approximately 649,889 shares were traded during mid-day trading, a decline of 34% from the average daily volume of 988,284 shares. The stock had previously closed at $0.3540.

Wall Street Analyst Weigh In

Several research firms recently commented on ITRM. Wall Street Zen cut shares of Iterum Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Iterum Therapeutics in a research note on Monday, December 22nd. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $9.00.

Iterum Therapeutics Price Performance

The stock has a market cap of $18.66 million, a price-to-earnings ratio of -0.47 and a beta of 2.87. The business has a fifty day moving average of $0.45 and a 200 day moving average of $0.66.

Iterum Therapeutics (NASDAQ:ITRM) last posted its earnings results on Friday, November 14th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.07). The business had revenue of $0.39 million for the quarter. On average, analysts expect that Iterum Therapeutics PLC will post -0.86 EPS for the current year.

Institutional Trading of Iterum Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Jane Street Group LLC bought a new stake in shares of Iterum Therapeutics during the 2nd quarter worth $92,000. Virtu Financial LLC acquired a new position in Iterum Therapeutics during the 3rd quarter worth $32,000. Finally, OneDigital Investment Advisors LLC boosted its holdings in Iterum Therapeutics by 18.6% during the third quarter. OneDigital Investment Advisors LLC now owns 191,000 shares of the company’s stock valued at $128,000 after acquiring an additional 30,000 shares during the period. 9.21% of the stock is currently owned by institutional investors and hedge funds.

About Iterum Therapeutics

Iterum Therapeutics plc is a clinical-stage biopharmaceutical company focused on the development and commercialization of anti-infective products targeting drug-resistant bacterial infections. The company’s research efforts are centered on novel therapeutic agents designed to address serious community-acquired and hospital-acquired infections where current treatment options are limited by emerging resistance.

The company’s lead product candidate, sulopenem, is being evaluated in both intravenous and oral formulations for the treatment of complicated urinary tract infections (cUTI) and intra-abdominal infections (IAI).